



E-cigarette flavor product stewardship – Best Practice

Dr Sandra Costigan, Principal Toxicologist Nicoventures, FDA Workshop 9 March 2015

Nicoventures – manufacturer of e-cigarettes

➤ Aim: To provide adult smokers wanting to reduce, replace or stop smoking with the best range of quality alternative products, delivering much of the experience they expect from a cigarette without the serious health risk of smoking.

➤ An autonomous business within the British American Tobacco Group



VYPE ePEN



Outline

Best practice in vaping flavor safety evaluations


- Introduction - Vype flavor safety assessment process
- Main points:
 - Ingredient purity requirements
 - Ingredient hazard exclusion screening
 - Inhalation data gap - In vitro cytotoxicity model
 - Exposure assessment data
 - Potential reaction and thermal breakdown products
- Summary

More detail in posters presented at Eurotox 2014, downloadable from www.BAT-science.com and in submitted manuscripts (Neilson et al, Costigan & Meredith)



Vype flavor safety assessment process

Ingredients




Thermal breakdown & reaction products

*CMR – Carcinogenic, Mutagenic, Toxic for Reproduction

Purity requirements – Pharma and food grade

- Require pharma grade for nicotine and humectants, food grade for flavor ingredients
 - Limits potential contaminants
 - Provides some qualitative reassurance on systemic toxicity
 - Provides some reassurance on quality assurance in the supply chain
- Full ingredient disclosure
 - CAS and FEMA#s
 - For naturals: botanical and geographical origin, extraction processes



Hazard exclusion screening – 1. No CMRs

Exclude CMR:

- IARC* group 1, 2A or 2B carcinogens
- FDA or harmonized EU classification
- If not evaluated for classification:
Weight of Evidence approach

*IARC – International Agency for Research on Cancer



*CMR – Carcinogenic,
Mutagenic, Toxic for
Reproduction



Hazard exclusion screening – 2. No respiratory sensitizers

Why?

- Relevant route of exposure
- Potential severity of symptoms
- Potentially very low derived tolerable levels
 - E.g. occupational exposure guidelines for isocyanates and anhydrides in $\mu\text{g}/\text{m}^3$, in ng/m^3 for several enzymes

Hazard identification is weight of evidence approach:

- Occupational exposure
- Literature data
- Regulatory classifications
- Compendiums

Note: contact sensitisation approach published in Eurotox 2014 poster, available at www.BAT-science.com




*CMR – Carcinogenic, Mutagenic, Toxic for Reproduction



Toxicological risk assessment – Review of existing data

- Review existing toxicological data, including occupational experience
- Local responses via other routes may help inform respiratory toxicity, e.g. irritation
- Use international scientific opinions where available (viz. JECFA, IARC)
- If no data on naturals – break down into separate constituents
- This should identify inhalation specific issues, e.g. diacetyl potential for bronchiolitis obliterans

Common finding: lack of inhalation data on flavors




Respiratory irritation – developed In vitro cytotoxicity model

- Appropriate cells/tissue – EpiAirway™
 - From species of interest: reconstruct from primary human cells
 - Relevant cell types: tracheobronchial epithelium
 - Realistic complexity: 3D fully differentiated, metabolically active. Includes variety of cell types, including mucus producing goblet cells, columnar cells, ciliated cells
- Exposure to the appropriate entity – the vaping aerosol
- Based on same principles as OECD 439 – Skin irritation cytotoxicity testing
 - Irritant criterium in OECD 439: 50% reduction in cell viability versus control

Submitted for publication: Neilson L, Mankus C, Thorne D, Jackson G, DeBay J, Meredith C




Test set up



Use in risk assessment – 1. Hazard identification

- ✔ No decrease in tissue viability over 6 hours continuous exposure
 - N=3 for e-cig samples, N=6 for air control

✔ This e-cigarette aerosol did not act as an irritant to the physiologically relevant respiratory epithelium




Use in risk assessment – 2. Comparison against a relevant benchmark

At whole product level

- E-cigarette aerosol (80/3/30) versus 3R4F smoke (35/2/60)
- **E-cigarette aerosol significantly less irritating than cigarette smoke**

At flavor ingredient level

- Demonstrate no difference in effect of aerosol from flavored formulation versus unflavored base liquid
 - Nicovertures support for menthol level in Vype




Consumer Exposure Data

- Exposure estimate requires quantitative data on how consumers use the product
 - Can vary between vaping products
 - Vape consumption and topography study – See “Frequency of use, Quantifying use and Topography” presentation in “E-cigarette topography” session
 - To protect majority of consumers, estimate “realistic worst case” exposure use using 95th %-ile data
- Topography data also informs testing regime to be used for chemical and biological testing, e.g.
 - When determining amount of ingredient per puff
 - Puffing regime used in aerosol in vitro testing model (80/3/30)



Potential thermal breakdown and reaction products

- Generate aerosol
 - For e-liquids sold separately, choose compatible device. Include information on test conditions in IFU
- Developed analytical method: TD-GC/MS-TOF
 - Specificity - Breadth of flavors, generally volatile
 - Accuracy - Detection limit based on TTC for unknown contaminants: 1.5 µg/day
 - Eg. If consumer data suggest 95th %-ile for a specific product type is 300 puffs/day → LOD 5ng/puff



Summary

Best practice in vaping flavor safety evaluations:

🌿 Ingredient purity requirements

- Pharma and food grade

🌿 Ingredient hazard exclusion screening

- Do not use CMRs and respiratory sensitizers

🌿 Inhalation data gap - In vitro cytotoxicity model

- Cells relevant to respiratory exposure
- Exposure to vaping product aerosol

🌿 Exposure assessment data

- Consumption and topography on relevant vaping product

🌿 Potential reaction and thermal breakdown products

- For flavorings: GC-MS, LOD based on consumer exposure estimate of 1.5 µg/day (i.e. 5 ng/puff if 300 puffs/day)





www.BAT-science.com

sandra_costigan@nicoventures.co.uk